Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 8/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28214406 | 1.00 | LMNA (0.50) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL21986977 | 1.00 | LMNA (0.50) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL11728391 | 0.97 | SMN1; SMN2 (0.48) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL28791831 | 0.95 | SMN1; SMN2 (0.50) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL10605396 | 0.90 | LMNA (0.65) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL19661642 | 0.90 | LMNA (0.65) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL1035585 | 0.90 | LMNA (0.65) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL22814372 | 0.90 | LMNA (0.65) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL9055861 | 0.90 | LMNA (0.65) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL1034608 | 0.90 | LMNA (0.65) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103130980-B | Preparation method for low free toluene diisocyanate (TDI) polyurethane pre-polymer curing agent | UNIV SOUTH CHINA TECH | 2015-07-01 | — | — | CN | claimed |
| CN-103130980-A | Preparation method for low free toluene diisocyanate (TDI) polyurethane pre-polymer curing agent | UNIV SOUTH CHINA TECH | 2013-06-05 | — | — | CN | claimed |
| CN-113372691-B | Resin composition, reinforcing liquid, reinforcing layer, and optical protective film | 宁波长阳科技股份有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-3990537-A1 | PRESSURE-SENSITIVE ADHESIVE COMPOUND WITH HIGH FILLER CONTENT | tesa SE (DE) | 2022-05-04 | — | — | EP | disclosed |
| CN-103130980-B | Preparation method for low free toluene diisocyanate (TDI) polyurethane pre-polymer curing agent | UNIV SOUTH CHINA TECH | 2015-07-01 | — | — | CN | disclosed |
| CN-103130980-A | Preparation method for low free toluene diisocyanate (TDI) polyurethane pre-polymer curing agent | UNIV SOUTH CHINA TECH | 2013-06-05 | — | — | CN | disclosed |
| EP-1981859-B1 | PREPARATION OF DELMOPINOL | SINCLAIR PHARMACEUTICALS LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-8093398-B2 | Preparation of delmopinol | Sinclair Pharmaceticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20110082301-A1 | Preparation of Delmopinol | COMELY ALEXANDER | 2011-04-07 | — | — | US | disclosed |
| US-7893258-B2 | Preparation of delmopinol | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20090036677-A1 | Preparation of Delmopinol | MAELOR LABORATORIES LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1981859-A2 | PREPARATION OF DELMOPINOL | Sinclair Pharmaceuticals Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091009-A2 | PREPARATION OF DELMOPINOL | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082301-A1 | Preparation of Delmopinol | CBR3, AVPR2, C1S | LMNA 1431/4885ALDH1A1 2640/4885HSD17B10 600/4885 |
| US-20090036677-A1 | Preparation of Delmopinol | AVPR2, CBR3, C1S | LMNA 1203/4885ALDH1A1 2718/4885HSD17B10 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.